Skip to main content
Equibles
NMRA logo

NMRA · Neumora Therapeutics, Inc. · Debt

Track NMRA — free

Use NMRA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NMRA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.04 -0.10 (-8.77%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“While the Company expects to be able to obtain additional funding, the current available cash and cash equivalents will not be sufficient to fund the Company’s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$195.41M
Shares
187.90M

Debt Profile

Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.

Debt data is being processed. Please check back later.
Key facts CIK 1885522 CUSIP 640979100 13F (30d) 45 filings 45 filers Visit website Investor relations